摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl (2E)-3-(2-hydroxy-3,5-dimethylphenyl)prop-2-enoate | 726190-96-1

中文名称
——
中文别名
——
英文名称
tert-butyl (2E)-3-(2-hydroxy-3,5-dimethylphenyl)prop-2-enoate
英文别名
Tert-butyl(2E)-3-(2-hydroxy-3,5-dimethylphenyl)prop-2-enoate;tert-butyl (E)-3-(2-hydroxy-3,5-dimethylphenyl)prop-2-enoate
tert-butyl (2E)-3-(2-hydroxy-3,5-dimethylphenyl)prop-2-enoate化学式
CAS
726190-96-1
化学式
C15H20O3
mdl
——
分子量
248.322
InChiKey
OEEJRLZRRCFJAI-VOTSOKGWSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.6
  • 重原子数:
    18
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    46.5
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    参考文献:
    名称:
    R-Isomers of Arg-Gly-Asp (RGD) mimics as potent αvβ3 inhibitors
    摘要:
    The integrin alpha(v)beta(3), vitronectin receptor, is expressed in a number of cell types and has been shown to mediate adhesion of osteoclasts to bone matrix, vascular smooth muscle cell migration, and angiogenesis. We recently disclosed the discovery of a tripeptide Arg-Gly-Asp (RGD) mimic, which has been shown to be a potent inhibitor of the integrin alpha(v)beta(3) and has excellent anti-angiogenic properties including its suppression of tumor growth in animal models. In other investigations involving RGD mimics, only compounds containing the S-isomers of the beta-amino acids have been shown to be potent. We were surprised to find the potencies of analogs containing enantiomerically pure S-isomers of beta-amino acids which were only marginally better than the corresponding racemic mixtures. We therefore synthesized RGD mimics containing R-isomers of beta-amino acids and found them to be relatively potent inhibitors of alpha(v)beta(3). One of the compounds was examined in tumor models in mice and has been shown to significantly reduce the rate of growth and the size of tumors. (c) 2007 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2007.03.034
  • 作为产物:
    参考文献:
    名称:
    R-Isomers of Arg-Gly-Asp (RGD) mimics as potent αvβ3 inhibitors
    摘要:
    The integrin alpha(v)beta(3), vitronectin receptor, is expressed in a number of cell types and has been shown to mediate adhesion of osteoclasts to bone matrix, vascular smooth muscle cell migration, and angiogenesis. We recently disclosed the discovery of a tripeptide Arg-Gly-Asp (RGD) mimic, which has been shown to be a potent inhibitor of the integrin alpha(v)beta(3) and has excellent anti-angiogenic properties including its suppression of tumor growth in animal models. In other investigations involving RGD mimics, only compounds containing the S-isomers of the beta-amino acids have been shown to be potent. We were surprised to find the potencies of analogs containing enantiomerically pure S-isomers of beta-amino acids which were only marginally better than the corresponding racemic mixtures. We therefore synthesized RGD mimics containing R-isomers of beta-amino acids and found them to be relatively potent inhibitors of alpha(v)beta(3). One of the compounds was examined in tumor models in mice and has been shown to significantly reduce the rate of growth and the size of tumors. (c) 2007 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2007.03.034
点击查看最新优质反应信息

文献信息

  • [EN] THE R-ISOMER OF BETA AMINO ACID COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES<br/>[FR] ISOMERE R DE COMPOSES D'ACIDES AMINES BETA EN TANT QUE DERIVES ANTAGONISTES DU RECEPTEUR DES INTEGRINES
    申请人:PHARMACIA CORPRATION
    公开号:WO2004060376A1
    公开(公告)日:2004-07-22
    The present invention relates to a class of compounds represented by the Formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula (I), and methods of selectively inhibiting or antagonizing the αVβ3 and/or the αV β5 integrin without significantly inhibiting the αV β6 integrin
    本发明涉及一类由公式(I)表示的化合物或其药用可接受的盐,包含公式(I)化合物的药物组合物,以及在不显著抑制αVβ6整合素的情况下选择性抑制或拮抗αVβ3和/或αVβ5整合素的方法。
  • R-isomer of beta amino acid compounds as integrin receptor antagonists derivatives
    申请人:Rogers Thomas
    公开号:US20050020505A1
    公开(公告)日:2005-01-27
    The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the α v β 3 and/or the α v β 5 integrin without significantly inhibiting the α v β 6 integrin.
    本发明涉及一类由公式I表示的化合物或其药学上可接受的盐,包括公式I化合物的制药组合物,以及选择性抑制或拮抗αvβ3和/或αvβ5整合素而不显著抑制αvβ6整合素的方法。
  • R-Isomers of Arg-Gly-Asp (RGD) mimics as potent αvβ3 inhibitors
    作者:Srinivasan R. Nagarajan、Balekudru Devadas、James W. Malecha、Hwang-Fun Lu、Peter G. Ruminski、Joseph G. Rico、Thomas E. Rogers、Laura D. Marrufo、Joe T. Collins、H. Peter Kleine
    DOI:10.1016/j.bmc.2007.03.034
    日期:2007.6.1
    The integrin alpha(v)beta(3), vitronectin receptor, is expressed in a number of cell types and has been shown to mediate adhesion of osteoclasts to bone matrix, vascular smooth muscle cell migration, and angiogenesis. We recently disclosed the discovery of a tripeptide Arg-Gly-Asp (RGD) mimic, which has been shown to be a potent inhibitor of the integrin alpha(v)beta(3) and has excellent anti-angiogenic properties including its suppression of tumor growth in animal models. In other investigations involving RGD mimics, only compounds containing the S-isomers of the beta-amino acids have been shown to be potent. We were surprised to find the potencies of analogs containing enantiomerically pure S-isomers of beta-amino acids which were only marginally better than the corresponding racemic mixtures. We therefore synthesized RGD mimics containing R-isomers of beta-amino acids and found them to be relatively potent inhibitors of alpha(v)beta(3). One of the compounds was examined in tumor models in mice and has been shown to significantly reduce the rate of growth and the size of tumors. (c) 2007 Elsevier Ltd. All rights reserved.
查看更多